Neurology

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chief scientific officer of FibroBiologics discussed efficacy findings from a phase 1/2 trial.

The professor from National Taiwan University Hospital discussed the importance of Rare Disease Day for raising awareness.

Clinical and industry leaders share their perspectives on the importance of collaboration in developing treatments for rare diseases.

Crystal Proud, MD, outlines advances in technology and research in neuromuscular diseases.

Review top news and interview highlights from the week ending February 25, 2022.

The chief scientific officer and senior vice president of the Parkinson’s Foundation discussed the organization’s initiative to advance genetic testing.

Cory Nicholas, PhD, cofounder and chief executive officer, Neurona Therapeutics, discussed the company’s lead program in mesial temporal lobe epilepsy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chief scientific officer of FibroBiologics discussed the benefits of fibroblast cell technology in MS.

The FDA cleared SBT-101's investigational new drug application earlier in February 2022.

Review top news and interview highlights from the week ending February 18, 2022.

Myrtelle’s therapy targets oligodendrocytes to deliver a functional copy of the ASPA gene.

The global head of research and development at Atara Biotherapeutics discussed the link between EBV and MS.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA has approved LEXEO Therapeutics’ investigational new drug application.

Interim safety data from the FORTIS study were presented at WORLDSympsoium.

The chief scientific officer of FibroBiologics discussed the advantages of fibroblast cell therapy over stem cell therapy.

Positive results from a phase 1/2 study of AXO-AAV-GM1 were presented at WORLDSymposium.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

SwanBio previously presented positive preclinical data at the ESGCT 2021 meeting.

The positive news is countered by a report of a patient death in Taysha’s gene therapy program for GM2 gangliosidosis.

Review top news and interview highlights from the week ending January 28, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.